news
Press release
 
August 7, 2014
Published Robotic PCI Study Reveals Favorable Results with Respect to Patient Radiation Exposure, fluoroscopy Time, and Contrast Volume

Robotic - assisted coronary angioplasties shows favorable over manual procedure

Waltham, MA – August 7, 2014Corindus Vascular Robotics, the leader in precision vascular robotics, today announced that the Journal of Invasive Cardiology published the results of a retrospective study comparing use of radiation and contrast for patients enrolled in its CorPath® PRECISE (Percutaneous Robotic - Enhanced Coronary Intervention) study to a matched traditional manual PCI patient in the July 2014 issue (Vol. 26, Issue 7, 2014). Results of the study demonstrate the CorPath System provides significantly lower harmful radiation exposure to the patient when CorPath is used for the complete intervention.

“The study results support many of the key benefits of the CorPath System, including lower radiation exposure, fluoroscopy time and contrast volume, which benefit not only the interventional cardiologist but also the patient,” said David Handler, president and CEO of Corindus. “As the adoption of CorPath expands in cath labs across the country, we are motivated by the continued success of our customers who also believe in the need for improvement over current techniques and the benefits offered by CorPath.”

The paper, authored principally by Giora Weisz, M.D., Chairman of Cardiology, Shaare Zedek Medical Center, Jerusalem, Israel, compared the outcomes of 40 patients that underwent PCI procedures at a single site in the PRECISE Trial using the CorPath robotic system to the 80 consecutive patients who met the same inclusion criteria but underwent conventional, manual PCIs at the same center.

Based on the research presented, the study demonstrates that the CorPath can lower radiation, fluoros copy and contrast versus a traditional, manual PCI. In the 38 cases in which the intervention was done exclusively with robotic - assistance the findings revealed that robotic - enhanced PCI

  • Decreased radiation dose (1347±482 mGy vs 1665±1026 mGy, P=0.04) for the patient and the operator;
  • Decreased fluoroscopy time (9.3±3.4 min vs. 12.3±7.6min, P=0.01)
  • Reduced contrast volume (119±47 mL vs 137±62 mL, P=0.07)

Corindus’ CorPath System is the first FDA - cleared medical device to bring robotic - assisted precision and accuracy to coronary angioplasty procedures, traditionally performed manually by the interventional cardiologist. During a CorPath robotic angioplasty procedure, the interventional cardiologist sits in the radiation shielded interventional cockpit, and advances stents and guidewires with millimeter by millimeter precision to physically open an artery blockage and help improve blood flow.

“Since completing the PRECISE Study, Corindus has maintained a strong commitment to clinical research, as evidenced by our coordination of the ongoing PRECISION Registry, also led by Dr. Weisz,” added Handler. “We are investing in such research programs to quantify the physician and patient benefits of the CorPath System, as well as investigate potential future indications such as peripheral, neurology and structural heart.”

For more information about CorPath, visit www.corindus.com.

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."

For additional information, visit www.corindus.com, and follow @CorindusInc.

Forward Looking Statements

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event

Examples of such statements include statements:

  • that the level of precision that can be attained using the CorPath GRX technology, combined with the potential for remote capabilities in the future, will both expand and improve how patients are treated;
  • that Corindus has entered a transformational period with a focus on expanding its reach to partner with hospitals to build robotic programs globally;
  • that the successful completion of these procedures at Fu Wai Hospital is the first step in Corindus' growth strategy within China; and that
  • the precise positioning enhancements to the CorPath platform that allows physicians to adjust guide catheters during PCI procedures may expand the use of the CorPath GRX System to more complex cases.

Media Contacts:

Corindus Vascular Robotics, Inc.

Kate Stanton
(508) 653-3335 ext. 200
kate.stanton@corindus.com

Investor Contact:

Lynn Pieper Lewis
(415) 937-5402
ir@corindus.com
 
close the window

Please complete the form below in order to download the content.








right
close the window

Please complete the form below in order to download the content.







close the window

Please fill out this brief form to subscribe to our email newsletter.





close the window

Please complete the form below and a member of our Clinical team will contact you.






close the window

Please complete the form below in order to download the content.







close the window
Thank you for subscribing to our newsletter. You will now receive email updates from Corindus.